News

The application, filed by Scolr on August 5, 2008, seeks approval to market a 120mg 12 hour pseudoephedrine tablet based on its patented Controlled Delivery Technology (CDT) platform.

Under the terms of the agreement S*BIO is eligible to receive up to $112.5 million in payments. This includes an upfront fee, development and sales milestone payments and

The double-blinded, randomized, placebo-controlled, dose ranging study is designed to evaluate the drug in about 180 pre-menopause obese women. The study is intended to confirm and extend previous

In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer. Labetuzumab is a non-internalizing humanized antibody that

The agreement provides for potential modification of select terms based on certain events and developments. The specific financial terms and conditions of the agreement have not been disclosed.

The technology is incorporated in the company’s AtherOx product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease. According to the company, the

Under the licensing agreement, Celldex has granted a worldwide fee- and royalty-bearing exclusive license to Vaccine Technologies (VTI) to develop and commercialize Celldex’s CholeraGarde and enterotoxigenic Escherichia coli

Grass Neurotrac III software has received the 510(k) clearance for the intended use of recording the electroencephalogram (EEG) and the computed EEG trends over extended periods of time

The testing performed by Accu-Chem includes analyses of body fluids and tissues for recognized toxic chemicals including chlorinated pesticides, volatile solvents, and polychlorinated biphenyls. These tests, which will